Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpCAM CAR-T cells + cyclophosphamide + fludarabine
- Development stage
- Unknown
- Lead developer
- Immunofoco
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal, Intravenous
01
Overview
This investigational combination therapy consists of intraperitoneally administered CAR-T cells targeting the Epithelial Cell Adhesion Molecule (EpCAM) and a lymphodepleting preconditioning chemotherapy regimen of cyclophosphamide and fludarabine. Developed by Jian-Kun Hu at West China Hospital, Sichuan University, the treatment is specifically designed for patients with advanced gastric cancer and peritoneal metastasis. The CAR-T cells are genetically engineered to recognize and eliminate EpCAM-expressing tumor cells, which are prevalent in gastric malignancies. The chemotherapy component (cyclophosphamide 300 mg/m² and fludarabine 30 mg/m²) is administered prior to the CAR-T cell infusion to deplete host lymphocytes, thereby creating a more favorable environment for the expansion, persistence, and anti-tumor activity of the infused cell therapy.
- Other names
- chemotherapy-Jian-Kun Hu-gastric cancerEpCAM-targeted CAR-T cellsintraperitoneal EpCAM CAR-T cellsEpCAM CAR-T
02
Targets
DNAEPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on EpCAM CAR-T cells + cyclophosphamide + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpCAM CAR-T cells + cyclophosphamide + fludarabine.